My statement is one step closer to validation. See the linked paper. "An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)" https://t.co/xNOgI1QCEJ https://t.co/WcTxfWK8ur
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
#JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) https://t.co/iafghdF4Dk https://t.co/tr5mROqoim
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
Peripheral blood PD1 occupancy by pembro is quick (3wks)...less so in tumor. RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) https://t.co/Ley7xfunBs h
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
RT @sitcancer: #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evalua…
#JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) https://t.co/iafghdF4Dk https://t.co/YwMBC0LkC2
RT @sitcancer: New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response ev…
RT @sitcancer: New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response ev…
RT @sitcancer: New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response ev…
Beautiful paper, congrats to researchers
RT @sitcancer: New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response ev…
RT @sitcancer: New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response ev…
New #JITC Research: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) https://t.co/iafghdF4Dk https://t.co/NE4ztVXNyA